Molecular Therapeutics in Non-Small Cell Lung Cancer

February 28, 2021

The clinical management of lung cancer is advancing at a rapid pace.  In particular, the identification of driver mutations and delineation of the molecular signature of lung cancers have resulted in significant improvements in the front-line treatment of both localized and advanced lung adenocarcinomas. ‘Molecular Therapeutics in Non-Small Cell Lung Cancer: A Virtual International Conference’ is a CME-accredited virtual conference which brings together the leading experts from around the world to discuss recent advances in the management of non-small cell lung cancer with a focus on biomarker-driven therapies, immuno-oncology, and clinical applications of the recent advances in non-small cell lung cancer, especially adenocarcinoma histology. This meeting will provide an opportunity to hear from the leading national and international experts on how recently published data would change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of non-small cell lung cancers in the near future.

This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:

  • Advances in the diagnosis & identification of molecular driver mutations
  • Choice and sequencing of therapeutic options based on molecular mutation changes
  • Use of molecular treatments in the adjuvant/curative setting
  • Trends in the use of checkpoint inhibitors in curative and palliative therapy

REGISTRATION FEES: 

Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies (An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients).

Please proceed to registration and select "non-industry learner" if you are a healthcare provider involved in patient care and are not an employee of an ineligible company. Your fee will reset to $0.00.

If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course.

Target Audience

This activity is directed toward medical oncologists who treat patients with lung cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of lung cancer are also invited to participate.

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Discuss the nuances of the use of plasma- vs tissue-based molecular diagnostic testing
  • Review recent data on the use of molecular targeted therapy in the adjuvant setting
  • Summarize emerging data on the use of newly-available driver mutation testing and the targeted therapies available
  • Explore the newest data on the therapeutic uses of checkpoint inhibitor therapy.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Course opens: 
02/08/2021
Course expires: 
03/31/2021
Event starts: 
02/28/2021 - 7:30am
Event ends: 
02/28/2021 - 11:30am
Cost:
$1.00
All times are listed in Pacific Standard Time (PST)
 
February 28, 2021 

Moderator – Dr. Joseph Rosales

7:15 AM – Zoom access opens (host will let you in)

7:15 AM to 7:35 AM – Networking with peers

7:35 AM to 7:45 AM PST:     Exhibit presentation by Amgen Inc in the Main Exhibit Breakout Room

7:45 AM to 7:55 AM PST:     BTF presentation by Dr. Binay Shah – Main Meeting room

7:55 AM to 8:00 AM PST:     Welcome & faculty introduction by Dr. Joe Rosales 

8:00 AM to 8:20 AM PST:     Advances in the detection of molecular driver mutations in lung adenocarcinoma, tissue vs plasma detection methods by Dr. Sandip Patel

8:20 AM to 8:40 AM PST:     EGFR-targeted therapy in the adjuvant treatment of lung adenocarcinoma by Dr. Narjust Duma

8:40 AM to 9:00 AM PST:     Discussion

9:00 AM TO 9:30 AM PST:     BREAK/EXHIBIT - All exhibit presentations will be held in the Main Exhibit Breakout Room

9:30 AM to 9:50 AM PST:     Emerging targets for molecular therapy – an expanding array of targetable driver mutations in advanced lung adenocarcinoma by Dr. Tejas Patil.

9:50 AM to 10:10 AM PST:  Recent advances in the use of checkpoint inhibitors in the management of lung adenocarcinoma by Dr. Christina Baik.

10:10 AM to 10:30 AM PST: Discussion 

10:30 AM to 10:35 AM PST: Concluding remarks

 

This meeting is held virtually on Zoom. Register for the activity to participate.

Travel

Not Applicable.

Narjust Duma, MD

Assistant Professor of Medicine

University of Wisconsin, Madison, WI

Learn more

Joseph Rosales, MD

Hematologist/Medical Oncologist

Virginia Mason Medical Center, Seattle, WA

Learn more

Christina Baik, MD

Associate Professor of Medicine

University of Washington, Seattle, WA

Learn more

Tejas Patil, MD

Assistant Professor of Medicine

University of Colorado, Aurora, CO

Learn more

Sandip Patel, MD

Associate Professor of Medicine

University of California, San Diego, CA

Learn more

  

DISCLOsures

No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity with the exception of the following faculties:

  • Dr. Narjust Duma: Dr. Duma has served as consultant for the following ineligible companies: Pfizer, AstraZeneca, Jansen and Neogenomics/inivata.
  • Dr. Christina Baik: Dr. Baik has received research support from Celgene. In addition, research funding was provided by the following ineligible companies to the University of Washington, and not directly to Dr. Baik: BMS, Merck and Genentech.  
  • Dr. Sandip Patel: Dr. Patel has received research support and served as a consultant for the following ineligible companies: BMS, Merck, Roche/Genentech, AstraZeneca/MedImmune and Pfizer

All relevant financial relationships of individuals in control of the content have been identified and mitigated. 

If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved. 

COMMERCIAL SUPPORT DISCLOSURE:

This activity has been supported with an independent medical education grant from AstraZeneca, Inc.

 

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 2 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.


Nursing Contact Hours 

Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2 Contact Hours.


ABSM Maintenance of Certificate Recognition Statement: 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 0.00 Attendance
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.

Please support this meeting by visiting our sponsors and exhibitors in the main exhibit breakout room during the exhibit presentations.

Please note that exhibit presentations are promotional materials separate from the accredited activities. These presentations are held in the exhibit breakout room during designated exhibit hours. 

We encourage you to visit the main exhibit breakout room and each company's breakout rooms during exhibit and break hours. 

The following Exhibitors will be making exhibit presentations during the exhibit hours:

CompanyReps PresentingLink to Exhibit Materials and Rep Email
Bristol Myers Squibb

Bill Johanson

Laura Matson

Email: Laura.Matson@bms.com

https://binaytarafoundation.box.com/s/wq62xxk4wj7rlde60g9wnpe8sivhya1l

 

Guardant Health

Kim Schliesman

Email: kschliesman@guardanthealth.com

 
AstraZeneca, Inc.

Kay Waltz

Greg Fredette

Email: gregory.fredette@astrazeneca.com

https://binaytarafoundation.box.com/s/97tgdsu4db3kzs2h0d81h97l6nnwzmcl

Amgen, Inc.

Tracy Huson

Email: thuson@amgen.com

https://www.findkrasg12c.com

 

Takeda Oncology

Caroline Caldwell,

Theresa Lambert

Email: Theresa.Lambert@takeda.com

https://binaytarafoundation.box.com/s/iktv4tapy4f1k3430fakbs64ywpepxxy

 

 

Price

Cost:
$1.00
Please login or register to take this course.

Cancellation Policy

No cancellation

 

Refund Policy 

No refunds issued after enrollment.

Required Hardware/software

Computer & Internet